Adicet Bio Announces Poster Presentation at the Upcoming 2023 Molecular Targets and Cancer Therapeutics Conference
Preclinical study shows Adicet’s Allogeneic Gamma Delta T Cell Platform may be a Promising Approach for Prostate Cancer
Details of the poster presentation is as follows:
Abstract Title: Characterization of Allogeneic CAR γδ1 T Cell Therapy for Prostate Cancer Targeting a Novel Dimeric Epitope on PSMA (Prostate-Specific Membrane Antigen)
Poster Number: C117
Session Location: Level 2, Exhibit Hall D
Investor and Media Contacts
Stern Investor Relations, Inc.